Table 3.

Mulitvariate analysis of lymphoma and specific IgE (≥0.35 kU/L) for all cases and for all cases before treatment group

All cases
Before treatment group
Nn (%)OR* (95% CI)Nn (%)OR* (95% CI)
Controls52482 (15.6)Reference52482 (15.6)Reference
All lymphoma45650 (11.0)0.67 (0.45-1.00)24625 (10.2)0.66 (0.40-1.10)
Lymphoma subgroups
    NHL23931 (13.0)0.78 (0.49-1.25)11112 (10.8)0.64 (0.32-1.27)
    B cell37536 (9.6)0.66 (0.43-1.03)21519 (8.8)0.68 (0.45-1.03)
        CLL1024 (3.9)0.30 (0.10-0.86)854 (4.7)0.62 (0.38-1.04)
        Lymphoplasmatic lymphoma181 (5.6)0.42 (0.05-3.35)120 (0.0)0.68 (0.41-1.13)
        Splenic marginal zone230 (0.0)0.75 (0.23-2.47)190 (0.0)0.65 (0.39-1.07)
        Plasma cell myeloma675 (7.5)0.57 (0.21-1.50)344 (11.8)0.62 (0.38-1.02)
        Marginal zone B cell215 (23.8)1.81 (0.60-5.42)81 (12.5)0.73 (0.45-1.19)
        Follicular lymphoma344 (11.8)0.64 (0.21-1.98)111 (9.1)0.67 (0.41-1.09)
        Diffuse large-cell lymphoma7813 (16.7)1.12 (0.57-2.20)307 (23.3)0.71 (0.44-1.12)
        Other B-cell lymphoma324 (12.5)0.65 (0.21-2.04)162 (12.5)0.65 (0.39-1.06)
    HL4810 (20.8)0.69 (0.30-1.56)165 (31.3)0.64 (0.40-1.03)
    T-cell lymphoma334 (12.1)0.52 (0.15-1.85)151 (11.1)0.68 (0.42-1.11)
        Mycosis fungoides/Sézary162 (12.5)0.33 (0.04-2.85)60 (0.0)0.66 (0.40-1.08)
        Other T cell172 (11.8)0.82 (0.17-3.94)91 (11.1)0.67 (0.41-1.11)
  • * Adjusted for age, sex, center, smoking status, any treated asthma or eczema.

  • NHL category excludes CLL, MM, and HL.